BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12802795)

  • 1. EPO906 (epothilone B): a promising novel microtubule stabilizer.
    Rothermel J; Wartmann M; Chen T; Hohneker J
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):51-5. PubMed ID: 12802795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilones: mechanism of action and biologic activity.
    Goodin S; Kane MP; Rubin EH
    J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epothilones: a novel class of non-taxane microtubule-stabilizing agents.
    Altaha R; Fojo T; Reed E; Abraham J
    Curr Pharm Des; 2002; 8(19):1707-12. PubMed ID: 12171542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
    Fumoleau P; Coudert B; Isambert N; Ferrant E
    Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
    Altmann KH; Memmert K
    Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
    Kamath K; Jordan MA
    Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical investigations with epothilones in breast cancer models.
    Burris HA
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
    Mok TS; Choi E; Yau D; Johri A; Yeo W; Chan AT; Wong C
    Oncology; 2006; 71(3-4):292-6. PubMed ID: 17657173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
    Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
    Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells.
    Rogalska A; Gajek A; Marczak A
    Phytomedicine; 2019 Aug; 61():152847. PubMed ID: 31029905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
    Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
    Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.